Skip to main content

Table 3 Recurrence pattern of patients with early-stage disease at first diagnosis (n = 13)

From: 18F-FDG PET/CT-based metabolic metrics in recurrent tumors of ovarian clear cell carcinoma and their prognostic implications

No Age Stage PFS (Months) Platinum response CA125 (U/mL) Relapsed tumor SUVmax Second-line treatment Status at last follow-up PRS (Months) OS (Months)
1 51 II 24 Sensitive 52.56 Vaginal cuff (−)a SCS + Chemo Alive 126 150
2 47 I 48 Sensitive 3.90 Vaginal cuff (−)a SCS + Chemo Alive 94 142
3 53 II 13 Sensitive 10.50 Pelvic tumor 7.2 SCS + Chemo Dead 29 42
4 54 I 19 Sensitive 4.9 Lung 3.4 SCS + Chemo Alive 95 114
5 54 I 31 Sensitive 48.60 Multiple lymph nodes 4.7 SCS + Chemo Dead 43 74
6 53 II 6 Resistant 11.24 Abdominal wall tumor, liver, rectal tumor 13.4 SCS + Chemo Dead 6 12
7 59 I 20 Sensitive 21.63 Multiple lymph nodes 7.9 SCS + Chemo Dead 10 30
8 60 I 108 Sensitive 115.30 Supra-diaphragmatic lymph node, Intestinal mesentery, pelvic tumor, vaginal cuff 14.3 SCS + Chemo Alive 36 144
9 36 I 34 Sensitive 8.31 Spleen 5.4 SCS + Chemo Dead 24 58
10 46 I 9 Resistant 23.74 Abdominal wall tumor 9.0 SCS + Chemo Alive 18 27
11 62 I 6 Resistant 40.65 Pelvic tumor 4.9 SCS + Chemo Alive 13 19
12 34 II 34 Sensitive 154.30 Multiple lymph nodes, peritoneum, liver 20.6 Chemo Alive 15 49
13 48 I 13 Sensitive 32.21 Pelvic tumor 5.0 SCS Unknownb Unknownb Unknownb
  1. aTwo patients presented with low glucose-uptake tumor
  2. bThis patient lost follow up after second cytoreduction surgery in our hospital
  3. Abbreviations: PFS Progression Free Survival, SUVmax Maximum Standardized Uptake Value, PRS Post-Relapse Survival, OS Overall Survival, SCS Secondary Cytoreduction Surgery, Chemo Chemotherapy